title: Vasculitis update, 2007.
abstract: Vasculitic syndromes are among the most complicated diseases to treat and manage. New medications and new ways of using old medications have provided us with new therapies to treat our patients. This review focuses on recent date that may have an impact on the way vasculitis is treated.
authors.affiliation: New York University School of Medicine, and Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA. Yusuf.yazici@nyumc.org
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yazici
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D013700:Giant Cell Arteritis / Q000188:drug therapy*; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D018501:Antirheumatic Agents; D003520:Cyclophosphamide; D001241:Aspirin; D008727:Methotrexate